 Teri Schreiner
Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 41 | 2025 | 455 | 5.530 |
Why?
| | Neuromyelitis Optica | 4 | 2023 | 132 | 1.160 |
Why?
| | Myelitis | 4 | 2020 | 107 | 0.890 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 5 | 2025 | 76 | 0.810 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 42 | 0.760 |
Why?
| | Cerebral Veins | 1 | 2021 | 16 | 0.700 |
Why?
| | Immunosuppressive Agents | 6 | 2024 | 894 | 0.690 |
Why?
| | Central Nervous System Diseases | 1 | 2021 | 69 | 0.670 |
Why?
| | Cerebral Hemorrhage | 1 | 2021 | 108 | 0.660 |
Why?
| | Microvessels | 1 | 2021 | 88 | 0.650 |
Why?
| | Nervous System Diseases | 4 | 2019 | 266 | 0.630 |
Why?
| | Sarcoidosis | 1 | 2021 | 160 | 0.600 |
Why?
| | Venous Thrombosis | 1 | 2021 | 190 | 0.600 |
Why?
| | Cognitive Dysfunction | 4 | 2025 | 383 | 0.570 |
Why?
| | Enterovirus Infections | 5 | 2020 | 177 | 0.560 |
Why?
| | Immunologic Factors | 5 | 2025 | 236 | 0.530 |
Why?
| | Child | 44 | 2025 | 21989 | 0.530 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 4 | 2024 | 51 | 0.520 |
Why?
| | Movement Disorders | 1 | 2017 | 58 | 0.520 |
Why?
| | Adolescent | 41 | 2025 | 21574 | 0.520 |
Why?
| | Muscular Diseases | 1 | 2017 | 114 | 0.510 |
Why?
| | Dimethyl Fumarate | 1 | 2016 | 12 | 0.500 |
Why?
| | Recurrence | 8 | 2025 | 1061 | 0.450 |
Why?
| | Rituximab | 4 | 2024 | 176 | 0.440 |
Why?
| | HLA-DRB1 Chains | 5 | 2023 | 113 | 0.400 |
Why?
| | Gene-Environment Interaction | 3 | 2023 | 192 | 0.400 |
Why?
| | Demyelinating Diseases | 3 | 2023 | 85 | 0.390 |
Why?
| | Genetic Predisposition to Disease | 6 | 2023 | 2427 | 0.360 |
Why?
| | Male | 48 | 2025 | 67906 | 0.340 |
Why?
| | Epstein-Barr Virus Infections | 2 | 2022 | 98 | 0.340 |
Why?
| | Magnetic Resonance Imaging | 9 | 2025 | 3577 | 0.340 |
Why?
| | Paralysis | 3 | 2016 | 71 | 0.340 |
Why?
| | Humans | 66 | 2025 | 137782 | 0.330 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2025 | 804 | 0.330 |
Why?
| | Age of Onset | 8 | 2025 | 520 | 0.300 |
Why?
| | Female | 46 | 2025 | 73465 | 0.300 |
Why?
| | Central Nervous System Viral Diseases | 2 | 2020 | 79 | 0.290 |
Why?
| | Autoantibodies | 5 | 2024 | 1497 | 0.290 |
Why?
| | Vaccines | 1 | 2014 | 406 | 0.290 |
Why?
| | Muscle Hypotonia | 2 | 2020 | 33 | 0.290 |
Why?
| | Aquaporin 4 | 3 | 2023 | 94 | 0.280 |
Why?
| | Case-Control Studies | 12 | 2025 | 3569 | 0.280 |
Why?
| | Neuromuscular Diseases | 2 | 2020 | 132 | 0.280 |
Why?
| | Neuropsychological Tests | 4 | 2025 | 1025 | 0.270 |
Why?
| | Cognition Disorders | 2 | 2022 | 496 | 0.270 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1724 | 0.270 |
Why?
| | Sunlight | 2 | 2025 | 73 | 0.260 |
Why?
| | Fingolimod Hydrochloride | 2 | 2024 | 40 | 0.260 |
Why?
| | Adjuvants, Immunologic | 2 | 2020 | 226 | 0.250 |
Why?
| | Gonadal Steroid Hormones | 2 | 2017 | 140 | 0.240 |
Why?
| | Vaccination | 1 | 2014 | 1381 | 0.230 |
Why?
| | Treatment Outcome | 5 | 2024 | 10837 | 0.230 |
Why?
| | Transgender Persons | 3 | 2017 | 186 | 0.230 |
Why?
| | Vitamin D | 2 | 2019 | 397 | 0.220 |
Why?
| | Menarche | 1 | 2025 | 60 | 0.220 |
Why?
| | Disease Progression | 4 | 2025 | 2760 | 0.220 |
Why?
| | Enterovirus D, Human | 2 | 2016 | 88 | 0.210 |
Why?
| | Risk Factors | 13 | 2025 | 10407 | 0.200 |
Why?
| | Follow-Up Studies | 5 | 2025 | 5136 | 0.200 |
Why?
| | Axons | 1 | 2025 | 198 | 0.200 |
Why?
| | Environmental Exposure | 2 | 2018 | 579 | 0.200 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2023 | 28 | 0.200 |
Why?
| | Body Composition | 2 | 2017 | 684 | 0.190 |
Why?
| | Cognition | 3 | 2025 | 1157 | 0.190 |
Why?
| | Immunoglobulin G | 3 | 2022 | 893 | 0.190 |
Why?
| | Parents | 3 | 2025 | 1350 | 0.170 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 660 | 0.170 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 28 | 0.170 |
Why?
| | Cohort Studies | 7 | 2025 | 5750 | 0.160 |
Why?
| | Lipids | 1 | 2025 | 673 | 0.160 |
Why?
| | Muscle Weakness | 1 | 2020 | 88 | 0.160 |
Why?
| | Young Adult | 12 | 2025 | 13240 | 0.160 |
Why?
| | Clinical Trials as Topic | 1 | 2024 | 1052 | 0.160 |
Why?
| | Adult | 17 | 2025 | 38023 | 0.150 |
Why?
| | Retrospective Studies | 10 | 2025 | 15682 | 0.150 |
Why?
| | Glatiramer Acetate | 1 | 2019 | 18 | 0.150 |
Why?
| | Enterovirus | 1 | 2019 | 86 | 0.150 |
Why?
| | Heavy Ion Radiotherapy | 1 | 2018 | 1 | 0.150 |
Why?
| | Oxidoreductases | 1 | 2019 | 92 | 0.150 |
Why?
| | Education, Special | 1 | 2018 | 23 | 0.150 |
Why?
| | Child, Preschool | 9 | 2024 | 11105 | 0.150 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 2189 | 0.150 |
Why?
| | Disability Evaluation | 2 | 2020 | 290 | 0.140 |
Why?
| | Fluoxetine | 1 | 2018 | 54 | 0.140 |
Why?
| | Disease Susceptibility | 2 | 2017 | 347 | 0.140 |
Why?
| | Research Design | 1 | 2024 | 1139 | 0.140 |
Why?
| | Electromyography | 2 | 2017 | 400 | 0.140 |
Why?
| | B-Lymphocytes | 1 | 2023 | 847 | 0.140 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 460 | 0.130 |
Why?
| | Neural Conduction | 1 | 2017 | 86 | 0.130 |
Why?
| | Atrophy | 1 | 2017 | 184 | 0.130 |
Why?
| | Longitudinal Studies | 4 | 2025 | 2860 | 0.130 |
Why?
| | United States | 11 | 2025 | 14870 | 0.130 |
Why?
| | Recovery of Function | 1 | 2020 | 653 | 0.130 |
Why?
| | Developmental Disabilities | 1 | 2018 | 264 | 0.120 |
Why?
| | Sodium Chloride, Dietary | 1 | 2016 | 36 | 0.120 |
Why?
| | Communicable Diseases | 1 | 2018 | 159 | 0.120 |
Why?
| | Attitude | 1 | 2017 | 259 | 0.120 |
Why?
| | Dietary Fats | 1 | 2017 | 304 | 0.120 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2015 | 11 | 0.120 |
Why?
| | Prospective Studies | 7 | 2024 | 7623 | 0.120 |
Why?
| | Perception | 1 | 2017 | 359 | 0.110 |
Why?
| | Marijuana Abuse | 1 | 2017 | 233 | 0.110 |
Why?
| | Testosterone | 2 | 2017 | 409 | 0.110 |
Why?
| | Colorado | 4 | 2019 | 4576 | 0.110 |
Why?
| | Aging | 1 | 2025 | 1865 | 0.110 |
Why?
| | Paraplegia | 1 | 2014 | 60 | 0.110 |
Why?
| | Bone Remodeling | 1 | 2015 | 75 | 0.110 |
Why?
| | Nuclear Proteins | 1 | 2019 | 712 | 0.110 |
Why?
| | Marijuana Smoking | 1 | 2017 | 256 | 0.110 |
Why?
| | Motor Neurons | 1 | 2016 | 234 | 0.110 |
Why?
| | Hypersensitivity | 1 | 2017 | 257 | 0.110 |
Why?
| | Bacterial Vaccines | 1 | 2014 | 63 | 0.100 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 403 | 0.100 |
Why?
| | CD40 Antigens | 1 | 2014 | 89 | 0.100 |
Why?
| | Administration, Oral | 1 | 2016 | 816 | 0.100 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2014 | 137 | 0.100 |
Why?
| | Viral Vaccines | 1 | 2014 | 98 | 0.100 |
Why?
| | Antiviral Agents | 1 | 2018 | 744 | 0.100 |
Why?
| | Neuroimaging | 1 | 2014 | 260 | 0.100 |
Why?
| | MicroRNAs | 1 | 2019 | 692 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2836 | 0.090 |
Why?
| | Body Mass Index | 2 | 2017 | 2390 | 0.090 |
Why?
| | T-Lymphocyte Subsets | 1 | 2014 | 417 | 0.090 |
Why?
| | Herpesvirus 4, Human | 2 | 2022 | 166 | 0.090 |
Why?
| | Bone Density | 1 | 2015 | 489 | 0.090 |
Why?
| | Patient Outcome Assessment | 2 | 2023 | 131 | 0.090 |
Why?
| | Transcription Factors | 1 | 2019 | 1719 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2016 | 655 | 0.080 |
Why?
| | Ultraviolet Rays | 2 | 2023 | 396 | 0.080 |
Why?
| | Death, Sudden | 1 | 2009 | 24 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 148 | 0.080 |
Why?
| | Diet | 1 | 2017 | 1279 | 0.080 |
Why?
| | Vena Cava, Inferior | 1 | 2009 | 71 | 0.080 |
Why?
| | Disease Outbreaks | 3 | 2019 | 395 | 0.080 |
Why?
| | Constriction, Pathologic | 1 | 2009 | 245 | 0.070 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 77 | 0.070 |
Why?
| | Testicular Neoplasms | 1 | 2009 | 110 | 0.070 |
Why?
| | Alleles | 2 | 2023 | 892 | 0.070 |
Why?
| | Biomarkers | 4 | 2025 | 4154 | 0.070 |
Why?
| | Genotype | 2 | 2023 | 1917 | 0.070 |
Why?
| | Sweden | 2 | 2017 | 101 | 0.070 |
Why?
| | Middle Aged | 8 | 2025 | 33554 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5478 | 0.060 |
Why?
| | Referral and Consultation | 2 | 2024 | 786 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 5793 | 0.060 |
Why?
| | Risk | 2 | 2019 | 912 | 0.060 |
Why?
| | Demyelinating Autoimmune Diseases, CNS | 1 | 2024 | 3 | 0.060 |
Why?
| | Haplotypes | 2 | 2019 | 494 | 0.060 |
Why?
| | Phosphatidylethanolamines | 1 | 2025 | 77 | 0.060 |
Why?
| | Neurofilament Proteins | 1 | 2025 | 52 | 0.060 |
Why?
| | Influenza, Human | 1 | 2010 | 622 | 0.060 |
Why?
| | Phosphatidylcholines | 1 | 2025 | 147 | 0.050 |
Why?
| | Brain | 3 | 2024 | 2677 | 0.050 |
Why?
| | Memory and Learning Tests | 1 | 2022 | 1 | 0.050 |
Why?
| | Infant | 4 | 2020 | 9482 | 0.050 |
Why?
| | Azathioprine | 1 | 2022 | 55 | 0.050 |
Why?
| | Logistic Models | 2 | 2018 | 2075 | 0.050 |
Why?
| | Demography | 1 | 2023 | 291 | 0.050 |
Why?
| | Genome-Wide Association Study | 2 | 2019 | 1431 | 0.050 |
Why?
| | Pandemics | 1 | 2010 | 1639 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 413 | 0.050 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2022 | 132 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 233 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2025 | 1266 | 0.050 |
Why?
| | HLA Antigens | 1 | 2023 | 240 | 0.040 |
Why?
| | Aged | 5 | 2019 | 24001 | 0.040 |
Why?
| | Hospitalization | 1 | 2010 | 2200 | 0.040 |
Why?
| | Antigens, CD20 | 1 | 2020 | 29 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 268 | 0.040 |
Why?
| | HIV Infections | 1 | 2015 | 2837 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2025 | 2057 | 0.040 |
Why?
| | Prevalence | 2 | 2017 | 2734 | 0.040 |
Why?
| | DNA Methylation | 1 | 2025 | 643 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 11 | 0.040 |
Why?
| | HLA-A3 Antigen | 1 | 2019 | 6 | 0.040 |
Why?
| | HLA-B7 Antigen | 1 | 2019 | 7 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2022 | 840 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 35 | 0.040 |
Why?
| | Relative Biological Effectiveness | 1 | 2018 | 4 | 0.040 |
Why?
| | International Agencies | 1 | 2018 | 35 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 170 | 0.040 |
Why?
| | Mathematical Concepts | 1 | 2018 | 31 | 0.040 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2018 | 30 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 2077 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 76 | 0.040 |
Why?
| | Japan | 1 | 2018 | 115 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2023 | 778 | 0.040 |
Why?
| | Radiometry | 1 | 2018 | 50 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2018 | 141 | 0.040 |
Why?
| | Propensity Score | 1 | 2020 | 294 | 0.040 |
Why?
| | Germany | 1 | 2018 | 121 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 358 | 0.040 |
Why?
| | Cancer Care Facilities | 1 | 2018 | 38 | 0.040 |
Why?
| | Central Nervous System | 1 | 2020 | 258 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2018 | 268 | 0.040 |
Why?
| | Cyproterone Acetate | 1 | 2017 | 2 | 0.040 |
Why?
| | Waist-Hip Ratio | 1 | 2017 | 39 | 0.040 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 130 | 0.040 |
Why?
| | Biomedical Research | 1 | 2024 | 700 | 0.040 |
Why?
| | Geography, Medical | 1 | 2017 | 11 | 0.030 |
Why?
| | Radiation Oncology | 1 | 2018 | 82 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2017 | 49 | 0.030 |
Why?
| | California | 1 | 2019 | 431 | 0.030 |
Why?
| | Habits | 1 | 2017 | 49 | 0.030 |
Why?
| | Knowledge | 1 | 2017 | 55 | 0.030 |
Why?
| | Organ Size | 1 | 2018 | 477 | 0.030 |
Why?
| | Water Quality | 1 | 2017 | 32 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 386 | 0.030 |
Why?
| | Reading | 1 | 2018 | 135 | 0.030 |
Why?
| | Tumor Burden | 1 | 2018 | 309 | 0.030 |
Why?
| | Waist Circumference | 1 | 2017 | 143 | 0.030 |
Why?
| | Diet Surveys | 1 | 2017 | 95 | 0.030 |
Why?
| | Anthropometry | 1 | 2017 | 213 | 0.030 |
Why?
| | Mendelian Randomization Analysis | 1 | 2017 | 50 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2018 | 216 | 0.030 |
Why?
| | Family | 1 | 2021 | 671 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 305 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2017 | 259 | 0.030 |
Why?
| | Forecasting | 1 | 2018 | 389 | 0.030 |
Why?
| | Vegetables | 1 | 2017 | 157 | 0.030 |
Why?
| | Registries | 1 | 2024 | 2041 | 0.030 |
Why?
| | North America | 1 | 2017 | 313 | 0.030 |
Why?
| | Binding Sites | 1 | 2019 | 1303 | 0.030 |
Why?
| | Focus Groups | 1 | 2018 | 530 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 683 | 0.030 |
Why?
| | Gender Identity | 1 | 2016 | 124 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 1024 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1070 | 0.030 |
Why?
| | Genetic Testing | 1 | 2017 | 462 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1509 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 94 | 0.030 |
Why?
| | Estradiol | 1 | 2017 | 521 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 1997 | 0.030 |
Why?
| | Air Pollution | 1 | 2017 | 316 | 0.030 |
Why?
| | Parkinson Disease | 1 | 2019 | 498 | 0.030 |
Why?
| | Self Efficacy | 1 | 2017 | 396 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2014 | 501 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2014 | 228 | 0.030 |
Why?
| | Cell Separation | 1 | 2014 | 318 | 0.020 |
Why?
| | Self Report | 1 | 2017 | 829 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1775 | 0.020 |
Why?
| | Muscle Strength | 1 | 2015 | 322 | 0.020 |
Why?
| | Acute Disease | 1 | 2014 | 1007 | 0.020 |
Why?
| | Animals | 1 | 2014 | 36951 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1178 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1313 | 0.020 |
Why?
| | Autopsy | 1 | 2009 | 95 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6834 | 0.020 |
Why?
| | Autoimmunity | 1 | 2014 | 908 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 658 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2009 | 243 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 5081 | 0.010 |
Why?
| | Phenotype | 1 | 2014 | 3196 | 0.010 |
Why?
| | Asthma | 1 | 2017 | 2298 | 0.010 |
Why?
| | Age Factors | 1 | 2010 | 3305 | 0.010 |
Why?
|
|
Schreiner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|